startups digital health weight loss glp-1 Chasing the $100 Billion Market for Weight-Loss Drugs Four Strategies for Competing in

These new drugs are reshaping not only how obesity is treated but also how it is perceived as a persistent medical condition stemming from biological factors, not merely a matter of self-discipline or resolve

Future study should focus on several key directions: (1) investigating SYK expression, activity, and its correlation with metabolic markers and clinical outcomes in neurobiopsies of patients with AMAN and other immune neuropathies

Berneis, K., Oehri, M., Kraenzlin, M

Both are referenced here for laboratory research purposes only and are not approved for human consumption or medical use.

doi: 10.14814/phy2.13503 59 SchlatterP.BeglingerC.DreweJ.GutmannH